Amicus Therapeutics Stock

Detail	Data
Volume (24h):	472,391 shares
P/E Ratio:	/
Forward P/E:	60.32
EPS:	-0.34 USD
Forward EPS:	0.16 USD
Number of Shares:	298,806,016 shares
Market Capitalization:	2,883,747,072.00 USD

The interactive chart displays the price movement of Amicus Therapeutics shares and updates every 15 minutes. It shows both the current price and historical trends. The chart offers various time frames, including daily, weekly, or monthly views, as well as the entire trading history.

Disclaimer: The data provided is for informational purposes only. Despite our efforts to ensure accuracy, it may contain errors or be outdated. We strongly recommend verifying the data from other independent sources. No investment decisions should be made based on this information.

Dividend

Dividend	Value
Dividend Amount	According to our data, the company Amicus Therapeutics does not currently pay dividends.
Annual Yield %:	-
Ex-dividend Date:	-
5-Year Avg Yield %:	-
Payout Ratio:	-
Last Dividend Value:	-
Last Dividend Date:	-

Analyst Forecast

Most analysts have issued a buy recommendation for Amicus Therapeutics stock. The current number of analysts covering this company is 11. The highest target price is 21 USD, while the lowest target price is 12 USD. The median target valuation set by analysts is 17 USD. These forecasts and recommendations provide insight into how analysts view the future stock performance of Amicus Therapeutics.

Analysts	Recommendation
Issued Recommendation:	According to our data, the recommendation for Amicus Therapeutics stock is: buy
Number of Analysts:	11
Highest Target Price:	21 USD
Lowest Target Price:	12 USD
Median Target Price:	17 USD

Fundamental Indicators

Indicator	Data
Total Revenue:	493,671,008.00 USD
Net Income:	-104,688,000.00 USD
Price-to-Book (P/B):	16.11
PEG Ratio:	/
Exchange:	NasdaqGM
Industry:	Biotechnology
Sector:	Healthcare
Number of Employees:	500
Country:	United States

Where to Buy Amicus Therapeutics Stock?

You can purchase Amicus Therapeutics stock on the NasdaqGM under the ticker symbol: FOLD. Several stock brokers or banks offer trading services for these stocks. Popular stock brokers like XTB and eToro allow you to buy real stocks and ETFs with zero or minimal commissions. Banks usually charge higher fees. Remember, investing in stocks involves risks, so it's important to carefully consider your financial situation and investment goals.

*To verify the availability of specific stocks on the platform, it's a good idea to first open a free demo account. Not all stocks are available.

Real stocks and ETFs. Low minimum deposit, only 50 EUR. Option to copy trades. Advanced stock analysis and free education.

Trustpilot rating 4.4/5 Google play rating 4.2/5

Invest in Stocks with eToro

★★★★★ 5.0

Real stocks and ETFs + free demo account. Low fees + fast customer support. More than 5,200 instruments available for trading. Free training and education. Regular live streams on YouTube.

Trustpilot rating 3.6/5 Google play rating 4.5/5

Try Free Demo Account

★★★★☆ 4.8

Risk warning: Trading CFDs involves a high risk of financial loss. Between 51%-eToro -89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

More Information on Amicus Therapeutics Stock

Indicator	Value
Company Revenue:	493,671,008.00 USD
EBITDA:	23,089,000.00 USD - Positive EBITDA indicates profitable operations before interest, taxes, depreciation, and amortization.
Earnings Per Share:	-0.34 USD
Book Value Per Share:	0.60 USD
Total Cash:	249,756,992.00 USD
Total Cash per Share:	0.84 USD
Total Debt:	444,657,984.00 USD
Debt to Equity Ratio:	2.49
Quick Ratio	2.20
Current Ratio	3.15
Free Cash Flow	-10,718,250.00 USD
Operating Cash Flow	-26,517,000.00 USD
Gross Margins	89.99 %
EBITDA Margins	4.68 %
Operating Margins	17.53 %
Profit Margins	-21.21 %
Return on Assets	1.2 %
Return on Equity	-67.1 %
Earnings Growth (1 year)	-
Revenue Growth (1 year)	36.7 %
Quarterly Earnings Year-over-Year Growth	-
Market Capitalization	2,883,747,072.00 USD
Enterprise Value	3,078,376,704.00 USD
EV/Revenue	6.236
EV/EBITDA	133.327
Float Shares	241,076,498 shares
Shares Outstanding	298,806,016 shares
Held Percent Insiders	0.01 %
Held Percent Institutions	104.02 %
Shares Short	18,230,381
Shares Short Prior Month	19,596,120
Date Short Interest	2025-01-15
Short Percentage of Total Shares	6.10 %
Short Ratio	7.91
Beta	0.67
Short Percentage of Float	6.14 %
Implied Shares Outstanding	304,379,008

Frequently Asked Questions (FAQ)

1️⃣ Does Amicus Therapeutics pay dividends?

According to our data, the company Amicus Therapeutics does not pay dividends yet, even in 2025.

2️⃣ Where to buy Amicus Therapeutics shares?

Amicus Therapeutics shares are traded on the NasdaqGM stock exchange under the ticker: FOLD. You can buy or trade them through a variety of stock brokers who provide real stock trading services.

3️⃣ What is the forecast for Amicus Therapeutics shares?

According to our data, the recommendation for Amicus Therapeutics shares is from a total of 11 analysts. The average target price prediction is 17 USD per share.

4️⃣ What is the total number of shares and the value of Amicus Therapeutics on the stock exchange?

The total number of Amicus Therapeutics shares on the exchange is 298,806,016.00 shares, which at the current market capitalization gives the company a total valuation of 2,883,747,072.00 USD.